<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>14</Volume>
				<Issue>5</Issue>
				<PubDate PubStatus="epublish">
					<Year>2013</Year>
					<Month>05</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Retrospective Study of Predictors of Bone Metastasis in Prostate Cancer Cases</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>3289</FirstPage>
			<LastPage>3292</LastPage>
			<ELocationID EIdType="pii">27778</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br/&gt;&lt;b&gt;Introduction&lt;/b&gt;: The purpose of this study was to identify clinical profiles of patients with low risk of having bonemetastases, for which bone scanning could be safely eliminated. Materials and &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: This retrospective crosssectional study looked at prostate cancer patients seen in the Urology Departments in 2 tertiary centres over the11 year period starting from January 2000 to May 2011. Patient demographic data, levels of PSA at diagnosis,Gleason score for the biopsy core, T-staging as well as the lymph node status were recorded and analysed.&lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: 258 men were included. The mean age of those 90 men (34.9%) with bone metastasis was 69.2±7.3 years.. Logistic regression found that PSA level (P=0.000) at diagnosis and patient’s nodal-stage (P=0.02) were theonly two independent variables able to predict the probability of bone metastasis among the newly diagnosedprostate cancer patients. Among thowse with a low PSA level less than 20ng/ml, and less than 10ng/ml, bonemetastasis were detected in 10.3% (12 out of 117) and 9.7% (7 out of 72), respectively. However, by combiningPSA level of 10ng/ml or lower, and nodal negative as the two criteria to predict negative bone scan, a relativelyhigh negative predictive value of 93.8% was obtained. The probability of bone metastasis in prostate cancercan be calculated with this formula: -1.069+0.007(PSA value, ng/ml)+1.021(Nodal status, 0 or 1)=x Probabilityof bone metastasis=2.718x/1+2.718x. &lt;br/&gt;&lt;b&gt;Conclusion&lt;/b&gt;: Newly diagnosed prostate cancer patients with a PSA level of10ng/ml or lower and negative nodes have a very low risk of bone metastasis (negative predictive value 93.8%)and therefore bone scans may not be necessary.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Prostate Cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">bone metastasis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">bone scan</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Prostate specific antigen</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Gleason score</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_27778_41ea0a7bda4d52b7ddea47a64f03129f.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
